OR-USB-IF
27.8.2024 17:01:25 CEST | Business Wire | Press release
USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced the launch of the USB-IF Conformity to IEC 62680 (USB) Specifications Program. This new initiative is designed to assist Original Equipment Manufacturers (OEMs)/Original Device Manufacturers (ODMs) in conforming to the basic requirements of the European Union (EU) Common Charger Directive, which mandates the use of standardized charging technology across a wide range of portable battery-powered devices in the EU.
In response to the EU's 2022 approval of the common charger directive—which will take effect on January 1, 2025, for portable battery-powered devices and in 2026 for laptops—the USB-IF Conformity to IEC 62680 (USB) Specifications Program specifically addresses key aspects of the directive. These include portable battery-powered devices, USB Type-C® receptacles, USB Type-C cables and connectors, external power supplies (EPS), and the USB Power Delivery (USB PD) protocol for devices advertising more than 15 Watts.
“The USB-IF has enjoyed a longstanding relationship with IEC. We contributed the core USB specifications to IEC which, once adopted, became the IEC 62680 series of USB specifications,” said USB-IF President and Chief Operating Officer Jeff Ravencraft. “The EU mandate covers only a portion of the entire USB specifications. As the industry group responsible for developing and overseeing all aspects of the USB specifications and testing, the USB-IF's new program is designed to assist OEMs/ODMs in demonstrating conformity with the EU’s requirements of the common charger directive.”
The USB-IF Conformity to IEC 62680 (USB) Specifications Program creates a simple, cost-effective process for OEMs/ODMs to demonstrate conformity to the EU Common Charger Directive. Using the USB-IF program, OEMs/ODMs can have their USB Type-C products formally tested by USB-IF authorized independent test labs (ITLs). Upon successful completion of testing, OEMs/ODMs will receive documentation to demonstrate to the EU that their products conform to the IEC 62680 (USB) specifications. This streamlined process allows for a quick testing turnaround, ensuring that manufacturers can meet regulatory deadlines:
- OEMs will continue to register their products and submit test results through ITLs, following USB-IF’s already established process.
- A minimum set of required tests has been defined by the USB-IF to demonstrate baseline conformity.
- The USB-IF will review all test result submissions and provide official approval.
- A Vendor ID (VID) is required, and USB-IF will be utilizing a Test ID (TID) as a tracker reference.
"The USB-IF Conformity to IEC 62680 (USB) Specifications Program has been crafted to ensure that all submitted products undergo evaluation, focusing on the critical elements we believe are necessary for conforming with the EU mandate,” said USB-IF Chief Technology Officer and Chairman of the Board Abdul Ismail. “Our testing levels are designed to offer a precise and reliable assessment, enabling OEMs/ODMs to confidently show to the EU that their products conform to the regulatory obligations."
While the USB-IF Conformity to IEC 62680 (USB) Specifications Program provides a vital service to OEMs/ODMs by offering a formal method to demonstrate conformity to EU mandates, it is important to distinguish this from the more extensive USB-IF Compliance Program. The USB-IF Compliance Program offers in-depth testing that not only establishes conformity with the IEC 62680 specifications but also fully verifies a product's adherence to the comprehensive USB-IF specifications for data performance, reliability and interoperability. Additionally, fully certified products qualify to be able to use the Certified USB Logo, which consumers recognize and trust to provide what they have come to expect from USB products.
“While this program is not a full certification of USB technologies, it provides a formalized pathway for OEMs/ODMs to test their products quickly,” said Ravencraft. “We are confident this new program will help the industry achieve conformity so they can continue to sell their products in the EU marketplace."
An online public listing of OEMs/ODMs products that have passed the "USB-IF Conformity to IEC 62680 (USB) Specifications Program" is located on the USB-IF product search page at www.usb.org. This platform also differentiates between products that are fully USB-IF certified and those that have met only the conformity requirements.
About USB-IF
The non-profit USB Implementers Forum, Inc. was formed to provide a support organization and forum for the advancement and adoption of USB technology as defined in the USB specifications. USB-IF facilitates the development of high-quality compatible USB devices through its logo and compliance program and promotes the benefits of USB and the quality of products that have passed compliance testing. Further information, including postings of the most recent product and technology announcements, is available by visiting the USB-IF website at www.usb.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827576634/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom